Conclusions:Both urine cotinine and NNAL are sensitive and specific biomarkers for discriminating the source of tobacco smoke exposure. Cotinine is the best overall discriminator when biomarkers are measured while a person has ongoing exposure to tobacco smoke. NNAL because of its long half-life would be particularly useful when there is a delay between exposure and biomarker measurement. The NNAL/cotinine ratio provides similar sensitivity but poorer specificity at discriminating passive versus active smokers when compared with NNAL alone.
IntroductionBiomarkers are useful in assessing both active and passive smokers' exposure to tobacco smoke. Self-reported exposure such as cigarettes smoked per day by active smokers and hours per day exposed to secondhand smoke (SHS) in passive smokers is imprecise. Exposure patterns differ significantly from person to person due to differences in how cigarettes are smoked, differences in tobacco products, room ventilation, proximity of smokers to nonsmokers, and many other environmental factors (N. L. Benowitz, 1996).Biomarkers are used to discriminate active from passive smokers in epidemiological studies, population surveillance of tobacco use, and research on the health risks of active and passive smoking. Determination of optimal biomarker cutoff Abstract Objectives: Cotinine is the most widely used biomarker to distinguish active versus passive smoking. However, there is an overlap in cotinine levels when comparing light or occasional smokers versus heavily exposed passive smokers. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is a tobacco-specific nitrosamine measurable in urine with a much longer half-life than cotinine. The aim of the study was to determine optimal cutoff points to discriminate active versus passive smokers and to compare sensitivity and specificity for the use of cotinine, NNAL, and the ratio of the NNAL/cotinine in urine.Methods: Cotinine and NNAL were measured in urine of 373 active smokers and 228 passive smokers.Results: Geometric mean cotinine levels were 2.03 ng/ml (interquartile interval: 0.43-8.60) and 1,043 ng/ml (658-2,251) and NNAL levels were 5.80 pg/ml (2.28-15.4) and 165 pg/ml (90.8-360) pg/ml in passive and active smokers, respectively. NNAL/cotinine ratio in urine was significantly higher for passive smokers when compared with active smokers (2.85 vs. 0.16, p < .01). The receiver operating characteristics analysis determined optimal cutoff points to discriminate passive versus active smokers: 31.5 ng/ml for cotinine (sensitivity: 97.1% and specificity: 93.9%), 47.3 pg/ml for NNAL (87.4% and 96.5%), and 0.74 × 10 −3 for NNAL/cotinine ratio (97.3% and 87.3%).